XT
ARQT icon

XTX Topco’s Arcutis Biotherapeutics ARQT Stock Holding History

XTX Topco’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Sell
42,684
-31,674
-43% -$808K 0.02% 1412
2025
Q4 		$2.16M Buy
74,358
+63,055
+558% +$1.61M 0.06% 518
2025
Q3 		$213K Sell
11,303
-26,252
-70% -$414K 0.01% 1796
2025
Q2 		$527K Sell
37,555
-36,121
-49% -$506K 0.02% 1064
2025
Q1 		$1.15M Buy
+73,676
New +$1.04M 0.06% 483
2024
Q4 		– Sell
-47,728
Closed -$444K – 2274
2024
Q3 		$444K Buy
47,728
+11,262
+31% +$111K 0.03% 902
2024
Q2 		$339K Buy
36,466
+25,793
+242% +$233K 0.03% 882
2024
Q1 		$106K Sell
10,673
-135,389
-93% -$1.01M 0.01% 1354
2023
Q4 		$472K Buy
146,062
+122,602
+523% +$333K 0.1% 295
2023
Q3 		$125K Buy
+23,460
New +$200K 0.02% 1152
2023
Q1 		– Sell
-12,222
Closed -$181K – 1259
2022
Q4 		$181K Buy
+12,222
New +$214K 0.04% 881

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return